Document is current

Article History

Received: 17 April 2024

Accepted: 24 September 2024

First Online: 17 October 2024

Declarations

:

: The VISIT STROKE study has been approved by the ethics committee (Charité Campus Mitte; Berlin/Germany; no. EA4_065_22 and subsequently by the responsible ethics committees in Brandenburg (2022-162-BO), Mecklenburg-Western Pomerania (BB 133/22a), Saxony-Anhalt (50/22), Saxony (EK-BR-8/23 − 1) University Hospital Dresden (BO-EK-328072022), University Hospital Heidelberg (S-666/2022), Rhineland Palatinate (2022–16853), Baden Wuerttemberg (B-F-2023-004), Hesse (V/1/ewa 2023-3294-zvBO) and the Data Protection Department of the Charité. Any changes to the study protocol, must be approved by the Ethics Committee before implementation. The study will be conducted in accordance with the Declaration of Helsinki in its current version, the guidelines of the International Conference on Harmonization of Good Clinical Practice (ICHGCP), and the applicable German laws. All patients or their legal guardians gave written informed consent prior to study participation.

: Not applicable.

: JH, HE, AA, JH, AA, AH, CG, SK, IS, GJ, HW, MA, CG, MH, JEW report no disclosures. AF has received consulting fees from Bayer, Roche, Novartis, Biogen Idec, and NovagoTherapeutics, and honoraria for oral presentations from Novartis, Böhringer-Ingelheim, Eli-Lilly and Company, Biogen Idec, Paul-Martini Stiftung, and Daiichi-Sankyo. HJA reports speaker fees and consultancy honoraria received during the conduct of the study from Bayer Vital, Boehringer Ingelheim Pharma, Bristol-Myers-Squibb, Novo Nordisk and Pfizer. TS reports speaker fees from Astrazeneca, royalties from Thieme and honoraria from Dresden International University.